The bivalent COVID-19 vaccine developed by GSK and Sanofi shows promising results with a 64.7% overall effectiveness against symptomatic COVID-19, according to a phase 3 trial. The vaccine performs especially well as a booster, achieving 75.9% efficacy in non-naïve subjects.
Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence – Pharmaceutical Technology
Biogen’s acquisition of HI-Bio’s anti-CD38 monoclonal antibody will expand its immunology presence. Image credit: Shutterstock / Tada Images. As Eli Lilly’s Kisunla (donanemab) enters the
July 3, 2024